What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy and safety of mosunetuzumab in untreated patients with follicular and marginal zone lymphoma.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomised trial achieved 90% complete response in untreated follicular lymphoma, suggesting efficacy of step-up dosing.

To evaluate the efficacy and safety of mosunetuzumab in untreated patients with follicular and marginal zone lymphoma.
Single center, open label, investigator-initiated clinical trial
Patients received subcutaneous mosunetuzumab for 8 cycles
Primary endpoint was complete response rate, assessing efficacy after therapy
100% overall response rate and 90% complete response rate observed
2-year progression-free survival of 88% for overall population
Neutropenia observed in patients, with rate of adverse events reported

Poh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark